Survival and Recurrence Patterns after Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophagogastric Adenocarcinoma

Annals of Surgical Oncology

Volumn 22, Issue 1, 2015, Pages 324-330

  Sudarshan, Monisha ^a   Alcindor, Thierry ^a   Ades, Steven ^b   Aloraini, Abdullah ^a   van Huyse, Marie ^a   Asselah, Jamil ^a   David, Marc ^a   Frechette, Dominique ^c   Brisson, Sonia ^c   Thirlwell, Michael ^a   Ferri, Lorenzo ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF VERMONT   (United States)

^c Gatineau Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA; ESOPHAGUS RESECTION; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADENOCARCINOMA; AGED; CANCER GRADING; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; LOWER ESOPHAGUS SPHINCTER; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR INVASION;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS;

EID: 84919776499     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3875-3     Document Type: Article

References (25)

1. DeMeester SR. Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res. 2009;3(2 Suppl 1):S2–5.
2. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236(3):376–84; discussion 384–5.
3. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908–14.
4. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
5. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
6. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.
7. Roth AD, Fazio N, Stupp R, et al. Docetaxel, cisplatin and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. J Clin Oncol. 2007;25(22):3217.
8. Ajani JA, Moiseyenko VM, Tjulandin S, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study group. J Clin Oncol. 2007;25(22):3205–9.
9. Ferri LE, Ades S, Alcindor T, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23(6):1512–7.
10. Reece-Smith AM, Saha S, Cunnell ML, et al. MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas. J Surg Oncol. 2012;106(6):748–52.
11. Francis AM, Sepesi B, Correa AM, et al. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013;258(3):500–7.
12. van Meerten E, Muller K, Tilanus HW, et al. Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer. 2006;94(10):1389–94.
13. Smit JK, Güler S, Beukema JC, et al. Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients. Ann Surg Oncol. 2013;20(12):4008–15.
14. Omloo JM, Lagarde SM, Hulscher JB, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000.
15. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22(11):2069–77.
16. Hulscher JB, van Sandick JW, de Boer AG, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;345(10):725–30.
17. Hagen JA, DeMeester SR, Peters JH, et al. Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg. 2001;234(4):520–30.
18. Feith M, Stein HJ, Siewert JR. Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients. Surg Oncol Clin N Am. 2006;15(4):751–64.
19. Fields RC, Strong VE, Gönen M, et al. Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastroesophageal adenocarcinoma. Br J Cancer. 2011;104(12):1840–7.
20. Alcindor T, Ferri LE, Marcus V, et al. Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome. Med Oncol. 2013;30(1):377.
21. Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol. 2013;31(34):4306–10.
22. Guo XF, Zhu XF, Zhong GS, Deng BG. Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. Dis Esophagus. 2013;26(5):487–95.
23. Okines AF, Langley RE, Thompson LC, et al. Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: A safety report. Ann Oncol. 2013;24(3):702–9.
24. Watson S, Validire P, Cervera P, et al. Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Ann Oncol. 2013;24(12):3035–9.
25. Shah MA, Wainberg ZA, Catenacci DV, et al. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer. PLoS One. 2013;8(3):e54014.